Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Rhea-AI Summary

Eton Pharmaceuticals (NASDAQ: ETON), a pharmaceutical company specializing in rare disease treatments, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025. The company will host a conference call and audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss the results.

Management will take live questions during the call and will also address emailed questions from investors sent to investorrelations@etonpharma.com. The webcast will be accessible through Eton's investor relations website and will remain available for 30 days after the event.

News Market Reaction – ETON

+2.18%

+2.18% Session move

In the trading session that priced this news, ETON gained 2.18%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Dial In* (Audio Only)        Click Here

Webcast:                          Click Here

In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.

The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

*Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:

Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals, Inc.

FAQ

When will Eton Pharmaceuticals (ETON) report Q1 2025 earnings?

Eton Pharmaceuticals will report its Q1 2025 earnings on Tuesday, May 13, 2025, followed by a conference call at 4:30 p.m. ET.

How can investors participate in Eton Pharmaceuticals' Q1 2025 earnings call?

Investors can participate through the audio webcast or dial-in after registering. They can also submit questions via email to investorrelations@etonpharma.com.

Where can I access the replay of Eton Pharmaceuticals' Q1 2025 earnings webcast?

The webcast replay will be available on Eton's investor relations website (ir.etonpharma.com) approximately two hours after the event and remain accessible for 30 days.

What is Eton Pharmaceuticals' main business focus?

Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases.